Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus
Launched by BANARAS HINDU UNIVERSITY · Sep 28, 2016
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
In our study patients were considered to have RSE if children were still having active convulsions despite receiving injection lorazepam intravenously at a dose of 0.1 mg/kg (max 4 mg) at a rate maximum upto 2 mg/min or intravenous diazepam at a dose of 0.2 - 0.3 mg/Kg (maximum 10 mg) slowly or intravenous midazolam at a dose of 0.15 - 0.2 mg/kg(max 5 mg). In case of children with difficult intravenous access buccal/nasal midazolam 0.2 - 0.3 mg/kg (maximum 5 mg) per rectal diazepam 0.5 mg/kg (maximum 10 mg) or intramuscular midazolam 0.2 mg/kg (maximum 5 mg). If seizure continued at 5 minut...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age - 1 year to 16 years
- • 2. Gender - male and female both
- • 3. Refractory generalized convulsive status epilepticus i.e. not responding to any two of the first line drugs
- Exclusion Criteria:
- • 1. Patients with epilepsia partialis continua.
- • 2. Patients with definite history of any allergic reaction to intravenous levetiracetam or intravenous valproate, or any contraindications in giving these drugs.
About Banaras Hindu University
Banaras Hindu University (BHU) is a prestigious institution located in Varanasi, India, renowned for its commitment to excellence in education and research across various disciplines, including medicine and health sciences. As a clinical trial sponsor, BHU leverages its robust academic infrastructure and multidisciplinary expertise to advance innovative research aimed at improving healthcare outcomes. The university fosters collaboration between researchers, healthcare professionals, and community stakeholders to ensure the ethical conduct and scientific rigor of its clinical trials, ultimately contributing to the advancement of medical knowledge and the development of effective therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Rajniti Prasad, MD
Study Director
Banaras Hindu University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials